Company intelligence / Profile preview
Charlesson
- Ownership
- Private
- Development stage
- Other
Overview
Charlesson is developing novel therapeutics for major retinal diseases such as diabetic retinopathy, age-related macular degeneration, and glaucoma. The company also provides specialty preclinical ophthalmic services to pharmaceutical companies. Clinical results or late-stage data are not detailed in public sources; the pipeline includes both early-stage research and development programs
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculeBiologic (inferred from focus on drug delivery and ophthalmic therapeutics)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Charlesson.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Charlesson.